125 Common Questions About Cannabis and Mental Health

Evidence-Based Answers From a Columbia University Psychiatrist

Concise, citable, research-backed answers to the most frequently asked questions about cannabis -- covering addiction, mental health, brain effects, teen use, products, medical cannabis, and legalization

1. What is cannabis?

Cannabis is a plant genus containing over 100 cannabinoids, primarily delta-9-THC (the psychoactive compound that produces the "high") and CBD (non-intoxicating). It has been used for millennia for medicinal, recreational, and industrial purposes. Common names include marijuana, weed, pot, and herb. Cannabis is classified as a Schedule I controlled substance under U.S. federal law.

2. What is THC?

THC (delta-9-tetrahydrocannabinol) is the primary psychoactive compound in cannabis. It produces the "high" by binding to CB1 receptors in the brain's endocannabinoid system, affecting mood, perception, appetite, pain, and cognition. THC content ranges from 15-25% in flower to 60-95% in concentrates. Higher concentrations are associated with greater mental health risks, including psychosis.

3. What is CBD?

CBD (cannabidiol) is a non-intoxicating cannabinoid. Unlike THC, it does not produce a "high." CBD has demonstrated anti-inflammatory, anxiolytic, and anticonvulsant properties. The FDA approved Epidiolex (pharmaceutical CBD) for certain seizure disorders. CBD may modulate some of THC's adverse effects, though this relationship is complex. Over-the-counter CBD products are minimally regulated.

4. How does cannabis work in the brain?

Cannabis activates the endocannabinoid system (ECS), a network of receptors (CB1, CB2) and neurotransmitters that regulate mood, pain, appetite, memory, and immune function. THC mimics natural endocannabinoids and overstimulates CB1 receptors, producing psychoactive effects. Chronic use downregulates these receptors, causing tolerance and dependence. The ECS also guides brain development during adolescence.

5. Is cannabis a drug?

Yes. Cannabis is a psychoactive substance that alters brain chemistry and function. It is classified as a Schedule I controlled substance under federal law. Being plant-derived does not change its pharmacological classification -- tobacco and opium are also plant-derived drugs. Cannabis meets the medical and scientific definition of a drug that produces tolerance, dependence, and withdrawal.

6. What is the endocannabinoid system?

The endocannabinoid system (ECS) is a biological signaling system in all mammals. It consists of endocannabinoids (anandamide, 2-AG), cannabinoid receptors (CB1 in the brain, CB2 in the immune system), and metabolic enzymes. The ECS regulates mood, pain, appetite, sleep, immune function, and brain development. THC hijacks this system by mimicking endocannabinoids at supraphysiological levels.

7. What is the difference between indica and sativa?

The traditional indica (sedating) vs. sativa (energizing) distinction is largely a marketing construct. Psychoactive effects are determined by the specific cannabinoid and terpene profile -- particularly the THC:CBD ratio -- not by indica/sativa classification. Most modern strains are hybrids. The distinction has some validity for plant morphology but is unreliable for predicting effects.

8. How long does a cannabis high last?

Duration depends on consumption method. Smoked or vaped: effects begin in seconds to minutes and last 1-3 hours. Edibles: effects begin 30-120 minutes after ingestion and can last 6-10 hours due to liver metabolism into 11-hydroxy-THC, a more potent metabolite. Individual tolerance, body composition, and product potency also influence duration.

9. How long does THC stay in your system?

THC metabolites are fat-soluble and persist long after effects subside. Urine: 3-30 days (up to 90 days for chronic heavy users). Blood: 1-7 days. Hair: up to 90 days. Saliva: 24-72 hours. Detection depends on use frequency, body fat percentage, metabolism, and test sensitivity. A positive test does not indicate current impairment.

10. What are cannabinoids?

Cannabinoids are compounds that interact with the endocannabinoid system. Three categories: phytocannabinoids (from cannabis -- over 100 identified, including THC and CBD), endocannabinoids (produced by the body -- anandamide, 2-AG), and synthetic cannabinoids (lab-created, like K2/Spice, which are significantly more dangerous than plant-derived cannabinoids).

11. What are terpenes?

Terpenes are aromatic compounds in cannabis (and many other plants) responsible for distinctive smells. Common cannabis terpenes include myrcene, limonene, linalool, and pinene. They may modulate THC's psychoactive effects through the "entourage effect," though research is emerging. Some terpenes have demonstrated anti-inflammatory or anxiolytic properties in preclinical studies.

12. What is hemp?

Hemp is legally defined as cannabis containing less than 0.3% THC (2018 Farm Bill). It is used for industrial purposes (fiber, textiles) and is the primary source of CBD products. Hemp cannot produce intoxication. The 0.3% threshold has created regulatory challenges, including delta-8 THC products derived from hemp that occupy a legal gray area.

13. Can you overdose on cannabis?

Fatal overdose from cannabis alone is extremely rare and essentially undocumented. However, cannabis can produce acute toxicity -- severe anxiety, paranoia, psychotic symptoms, tachycardia, and impaired motor function -- particularly from edibles or high-potency products. These episodes frequently result in ER visits. "Overdose" in cannabis typically means acute adverse reaction, not fatal poisoning.

14. Is secondhand cannabis smoke harmful?

Secondhand cannabis smoke contains toxicants similar to tobacco smoke (carbon monoxide, ammonia, carcinogens). Research suggests it can impair vascular function and may produce detectable THC levels in non-users in poorly ventilated spaces. Children, pregnant women, and people with respiratory conditions should avoid exposure.

15. What is the difference between THC and CBD?

THC is psychoactive (produces a high), binds directly to CB1 receptors, can cause anxiety and psychosis, and produces dependence. CBD is non-intoxicating, has a complex pharmacological profile, may have anti-anxiety and anti-inflammatory properties, and does not produce dependence. CBD may partially counteract some of THC's adverse effects.

16. Is weed addictive?

Yes. Approximately 22-30% of cannabis users develop cannabis use disorder (NIDA). Among adolescents, 1 in 6 users develop CUD (AACAP). Cannabis produces tolerance, withdrawal, craving, and compulsive use that meet DSM-5 criteria for a substance use disorder. The idea that cannabis is "not addictive" is a persistent myth contradicted by decades of research. See Cannabis Use Disorder.

17. Can you get physically dependent on cannabis?

Yes. Physical dependence is well-documented and DSM-5 recognized. Chronic use downregulates CB1 receptors, causing tolerance and withdrawal upon cessation. Physical dependence develops faster with high-potency products and daily use. Severity increases with duration and intensity of use.

18. What are cannabis withdrawal symptoms?

Cannabis withdrawal is a DSM-5 recognized syndrome affecting ~12.1% of frequent users. Symptoms begin 24-72 hours after cessation and last 1-2 weeks: irritability, insomnia, decreased appetite, anxiety, restlessness, depressed mood, abdominal pain, sweating, and intense cravings. Not medically dangerous but uncomfortable enough to drive relapse.

19. How long does cannabis withdrawal last?

Acute symptoms begin within 24-72 hours, peak in the first week, and largely resolve within 2-4 weeks. Some individuals experience protracted withdrawal (lingering insomnia, cravings, mood disturbance) lasting months. Heavier, longer-duration users of high-potency products have longer, more severe withdrawal.

20. What is cannabis use disorder?

Cannabis use disorder (CUD) is a DSM-5 diagnosis requiring 2+ of 11 criteria within 12 months: failed quit attempts, craving, tolerance, withdrawal, continued use despite harm, etc. Classified as mild (2-3 criteria), moderate (4-5), or severe (6+). Affects 22-30% of users. See Cannabis Use Disorder.

21. How do I know if I have a cannabis problem?

Key signs: using more than intended, unsuccessful attempts to cut down, significant time spent on cannabis, craving, failing obligations, continued use despite relationship problems, giving up activities, tolerance, and withdrawal. Meeting 2+ of these criteria suggests CUD. If you are asking this question, a professional evaluation is warranted.

22. How common is cannabis addiction?

CUD affects 22-30% of cannabis users (NIDA). Among teens, ~1 in 6 users (AACAP). Cannabis is the primary substance in 9.8% of all U.S. treatment admissions (TEDS 2023). CUD prevalence is increasing with rising THC potency and is widely underdiagnosed.

23. How do you quit using cannabis?

Evidence-based approaches: CBT (identify triggers, build coping skills), MET (build motivation), contingency management (reinforce abstinence). Treat underlying conditions driving use (anxiety, ADHD, depression). No FDA-approved medications exist yet. Set a quit date, remove paraphernalia, and have a withdrawal management plan. See CUD Treatment.

24. Can you be addicted to weed and not know it?

Yes. The widespread belief that cannabis is not addictive creates a cognitive barrier to recognition. Common rationalizations: "I can quit anytime," "It's just a plant," "I only use to relax." Gradual tolerance increases and narrowing of activities can occur so slowly the individual does not recognize the pattern.

25. Is cannabis harder to quit than people think?

Yes. Withdrawal (insomnia, irritability, anxiety, cravings) can last weeks. The psychological dependence -- reliance on cannabis for relaxation, sleep, and emotional regulation -- is often harder to overcome than physical withdrawal. Only 36.8% of adolescents complete CUD treatment (TEDS).

26. What is cross-tolerance?

Cross-tolerance occurs when tolerance to one substance extends to another with a similar mechanism. Cannabis and synthetic cannabinoids share CB1 receptor activation, producing cross-tolerance. Some research suggests partial cross-tolerance with alcohol at the endocannabinoid level. Cross-tolerance does not typically exist between cannabis and opioids or stimulants.

27. Does cannabis tolerance ever go away?

Yes. CB1 receptor density begins recovering within days of cessation and largely normalizes within 2-4 weeks. A "tolerance break" of 2-4 weeks significantly reduces tolerance, though returning to the same use pattern rapidly re-establishes it. Very long-term heavy users may take longer to fully recover.

28. Can you use cannabis without becoming dependent?

Yes. 70-78% of users do not develop CUD. Lower risk is associated with infrequent use, later onset (after 25), lower-potency products, no co-occurring mental health conditions, no family history of addiction, and social rather than solitary use for coping. However, no use pattern carries zero risk.

29. What is cannabinoid hyperemesis syndrome?

CHS is a condition in chronic heavy cannabis users characterized by severe cyclic nausea, vomiting, and abdominal pain. Hot showers provide temporary relief. CHS has become a significant ER presentation since high-potency products became widespread. The only definitive treatment is complete cessation. CHS resolves within days to weeks after quitting.

30. Is cannabis more addictive than alcohol?

Lifetime dependence risk is lower for cannabis (~22-30% of users) than for alcohol (~15% of drinkers develop AUD, but ~29% meet criteria at some point). However, comparisons are complicated by differences in use patterns, cultural norms, and potency variability. Both are addictive substances with real health consequences. Neither should be dismissed as harmless. See Is Cannabis Addictive?.

31. Does cannabis cause anxiety?

Cannabis has a biphasic relationship with anxiety. Low THC doses may reduce anxiety short-term; higher doses reliably increase it. High-potency products and edibles are common triggers for acute panic attacks. Chronic use is associated with higher rates of generalized anxiety disorder, social anxiety, and panic disorder.

32. Does cannabis cause depression?

Heavy chronic use is associated with higher depression rates. Early-onset use increases risk of developing depression. Cannabis may temporarily alleviate symptoms (driving self-medication) while worsening the condition through serotonin and dopamine disruption. Depressive symptoms often improve within weeks of cessation.

33. Can cannabis cause psychosis?

Yes. Daily high-potency cannabis use is associated with 5x the odds of first-episode psychosis (Di Forti et al., Lancet Psychiatry, 2019). The relationship is dose-dependent, potency-dependent, and age-dependent. Genetically vulnerable individuals face the highest risk. See Cannabis and Psychosis.

34. What is cannabis-induced psychosis?

A psychiatric condition where cannabis triggers hallucinations, delusions, paranoia, and disorganized thinking. Can occur acutely during intoxication or develop with chronic use. Approximately 50% of individuals who experience it later develop a chronic psychotic disorder such as schizophrenia. Highest risk with high-potency products and daily use.

35. Can cannabis worsen ADHD?

Despite anecdotal reports of symptom relief, cannabis worsens ADHD by impairing executive function, working memory, and sustained attention -- the cognitive domains already impaired in ADHD. Chronic use can also interfere with ADHD medication. Evidence-based ADHD treatment is more effective and carries fewer risks.

36. Does cannabis help with PTSD?

Some PTSD patients report short-term relief for hyperarousal and insomnia. However, controlled trials have not shown consistent benefit, and chronic use may impair fear extinction -- central to evidence-based PTSD therapies (CPT, PE, EMDR). Cannabis use in PTSD populations is associated with higher CUD rates.

37. Can cannabis cause schizophrenia?

Cannabis is a well-established risk factor for schizophrenia. A Danish registry study estimated up to 15% of schizophrenia cases among young men are attributable to CUD. Risk is highest with adolescent onset, daily use, high potency, and family history. Multiple lines of evidence support a causal relationship.

38. Does cannabis affect bipolar disorder?

Cannabis use in bipolar disorder is associated with more frequent episodes, more severe mania, worse treatment outcomes, and higher rates of rapid cycling. Cannabis can trigger manic episodes and interfere with mood stabilizers. Use rates are disproportionately high among bipolar patients, likely reflecting self-medication.

39. Can cannabis make you suicidal?

Heavy cannabis use is associated with increased suicidal ideation, attempts, and completed suicide, particularly among young people. A systematic review found a 2-fold increase in suicide risk (Borges et al., 2016). Mechanisms include worsened depression, intoxication-related impulsivity, and reduced help-seeking. If you are experiencing suicidal thoughts, contact 988.

40. Does cannabis worsen OCD?

Limited research suggests cannabis may temporarily reduce OCD-related anxiety without addressing the underlying obsessive-compulsive cycle. Some patients report worsening of obsessive thoughts with high-THC products. Standard OCD treatments (ERP therapy, SSRIs) remain the evidence-based standard. Cannabis is not a substitute.

41. Does cannabis affect sleep?

THC may help users fall asleep faster short-term but disrupts sleep architecture -- reducing REM sleep (critical for memory and emotional processing). Chronic use leads to poorer overall sleep quality. Rebound insomnia upon cessation can last weeks. CBD may have mild sleep-promoting effects without REM suppression.

42. Can cannabis cause panic attacks?

Yes. Cannabis is a well-documented panic trigger, particularly with high-THC products and edibles. High-dose THC activates the amygdala and increases norepinephrine, producing racing heart, chest tightness, derealization, and overwhelming dread. First-time and infrequent users are at highest risk.

43. Does cannabis help with anxiety?

The relationship is biphasic: low THC doses may mildly reduce anxiety; higher doses increase it. CBD may have anxiety-reducing properties. Chronic use is associated with higher anxiety disorder rates. Cannabis-induced anxiety is a top reason for cannabis ER visits. Evidence-based anxiety treatments (CBT, SSRIs) are safer and more effective.

44. Does cannabis affect motivation?

Chronic use is associated with reduced motivation ("amotivational syndrome"). THC blunts dopamine release in the reward system, reducing drive to pursue goals. Neuroimaging shows reduced ventral striatum activity in chronic users. Motivation typically improves within weeks to months of cessation.

45. Does cannabis affect emotional regulation?

Yes. Chronic use disrupts the ECS's role in modulating stress and emotions. Users develop reliance on cannabis as their primary emotional regulation tool while natural coping capacity atrophies. When cannabis is unavailable, the individual lacks coping skills, driving continued use and withdrawal irritability.

46. Can cannabis worsen social anxiety?

Many people with social anxiety use cannabis to cope with social situations. While it may reduce acute social anxiety at low doses, chronic use is associated with avoidance behavior, reduced social skill development, and worsening of the underlying social anxiety disorder. Reliance on cannabis for social situations prevents natural habituation and skill-building.

47. Does cannabis affect concentration?

Yes. THC impairs sustained attention, working memory, and task-switching through its effects on the prefrontal cortex and hippocampus. Acute impairment occurs during intoxication. Chronic users show deficits even when sober, though these partially improve with sustained abstinence. The attention impairment is particularly problematic for students and professionals requiring sustained focus.

48. Does cannabis cause depersonalization?

Yes. Cannabis, particularly at high doses or with high-potency products, can trigger depersonalization (feeling detached from yourself) and derealization (feeling the world is unreal). In some individuals, cannabis can precipitate depersonalization/derealization disorder that persists beyond the period of intoxication. This is more common with edibles and concentrates.

49. Can cannabis trigger mania?

Yes. Cannabis can trigger manic episodes in individuals with bipolar disorder or bipolar vulnerability. THC's stimulation of the dopaminergic system can precipitate the elevated mood, grandiosity, decreased need for sleep, and impulsive behavior characteristic of mania. Cannabis-triggered mania can occur even in individuals not previously diagnosed with bipolar disorder.

50. Does quitting cannabis improve mental health?

In most cases, yes. Research consistently shows that cessation of chronic cannabis use is associated with improvements in anxiety, depression, cognitive function, motivation, and sleep quality within 2-8 weeks. The initial withdrawal period (1-2 weeks) may temporarily worsen symptoms before improvement occurs. Individuals with cannabis-induced psychosis typically see symptom resolution with abstinence.

51. How does cannabis affect the brain?

THC binds to CB1 receptors in the prefrontal cortex (judgment), hippocampus (memory), amygdala (emotion), and cerebellum (coordination). Chronic use causes receptor downregulation, altered white matter, reduced hippocampal volume, and disrupted prefrontal function. Effects are more pronounced with adolescent onset. See Cannabis Brain Effects.

52. Does cannabis affect memory?

Yes. THC impairs hippocampal memory formation. Acute: disrupted short-term memory. Chronic: lasting verbal and episodic memory deficits. The Dunedin study linked persistent adolescent use to memory deficits not fully reversible with cessation. Memory improves with abstinence but may not return to baseline in long-term heavy users.

53. Does cannabis lower IQ?

The Dunedin study found persistent adolescent cannabis use associated with up to 8-point IQ decline not fully reversible. This effect was specific to adolescent-onset use -- adult-onset users did not show the same decline. Subsequent research has produced mixed results, with debate about confounding factors.

54. Does cannabis affect lung health?

Smoked cannabis exposes lungs to tar, carbon monoxide, and carcinogens. Regular smoking is associated with chronic bronchitis symptoms. Evidence for lung cancer is inconclusive. Vaping avoids combustion but introduces EVALI risk and unknown long-term inhalation effects from additives and heating elements.

55. Does cannabis affect heart health?

Cannabis acutely increases heart rate by 20-50 bpm, raises blood pressure, and can trigger arrhythmias. Emerging research links chronic heavy use to increased heart attack and stroke risk, particularly in younger users. Cannabis cardiovascular events have increased in ER data post-legalization.

56. Is cannabis safe during pregnancy?

No. All major medical organizations (ACOG, AAP, WHO) recommend against it. THC crosses the placenta. Prenatal exposure is associated with low birth weight, preterm birth, NICU admission, and neurodevelopmental effects in offspring. No amount has been established as safe during pregnancy.

57. Is cannabis safe while breastfeeding?

No. THC concentrates in breast milk at ~8x maternal plasma levels and transfers to the nursing infant. The developing infant brain is highly sensitive to cannabinoid exposure. ACOG and AAP recommend against use while breastfeeding. No safe level through breast milk has been established.

58. Does cannabis affect fertility?

Research suggests cannabis impairs fertility in both sexes. Males: reduced sperm count, motility, and morphology. Females: disrupted ovulation, egg maturation, and uterine receptivity. The ECS plays a role in reproductive function, and exogenous THC disrupts these processes. Couples trying to conceive should avoid cannabis.

59. Does cannabis affect testosterone?

Research is mixed. Some studies show acute THC suppresses testosterone; chronic users may develop compensatory mechanisms. A 2017 meta-analysis found modest, inconsistent effects. Clinical significance is debated, though testosterone changes may contribute to reproductive effects in male users.

60. Does cannabis affect weight?

Cannabis acutely stimulates appetite ("munchies") via CB1 activation in the hypothalamus. Paradoxically, epidemiological data shows cannabis users have slightly lower BMI and obesity rates. The mechanism is not fully understood. Cannabis should not be considered a weight management tool.

61. Can cannabis cause cancer?

Evidence is mixed. Cannabis smoke contains carcinogens; some studies link heavy smoking to head/neck and testicular cancers. Population studies have not found a consistent link to lung cancer. IARC has not classified cannabis as a known carcinogen. More research is needed.

62. Does cannabis affect the immune system?

Cannabis has immunomodulatory effects via CB2 receptors. THC can suppress T-cell proliferation and cytokine production. CBD has anti-inflammatory properties. Clinical significance in healthy individuals is unclear, but immunocompromised individuals should exercise caution.

63. Does cannabis affect coordination and reaction time?

Yes. Cannabis impairs psychomotor function, reaction time, divided attention, and coordination via cerebellar and prefrontal effects. Driving under the influence doubles accident risk (Asbridge et al., 2012). Impairment lasts 3-6 hours after inhalation, longer after edibles. Never drive after using cannabis.

64. Does cannabis affect bone health?

Emerging research suggests chronic heavy cannabis use may be associated with lower bone mineral density and increased fracture risk, possibly through CB1 receptor effects on osteoblast and osteoclast activity. However, the evidence is preliminary and the clinical significance for most cannabis users is uncertain.

65. Does cannabis affect dental health?

Cannabis smoking can cause dry mouth (xerostomia), which increases risk of tooth decay, gum disease, and oral infections. Some research links chronic cannabis use to higher rates of periodontal disease. Edible cannabis products high in sugar present additional dental caries risk. Regular dental care is advisable for cannabis users.

66. Does cannabis affect the teenage brain differently?

Yes. The brain develops until ~age 25. THC disrupts ECS signaling guiding neural pruning and myelination. Adolescent use is associated with reduced IQ, impaired memory, disrupted executive function, and 2-4x psychosis risk -- effects partially irreversible and not seen to the same degree with adult-onset use. See Teenage Brain.

67. What are signs a teen is using cannabis?

Red eyes, increased appetite, lethargy, declining grades, withdrawal from family, friend group changes, lost interest in hobbies, vape pens/edible packaging, mood swings, secrecy, sweet/skunky odor. Modern products leave fewer traces -- behavioral changes are most reliable. Look for clusters, not single signs. See Teen Cannabis Use.

68. When is the brain fully developed?

Approximately age 25, with the prefrontal cortex (judgment, impulse control) maturing last. The endocannabinoid system guides this development. Cannabis use before 25 carries unique neurological risks not present with later-onset use.

69. How should parents talk to kids about cannabis?

Start early (before high school), ask open-ended questions, share brain science without catastrophizing, focus on decision-making skills over obedience, listen more than talk, avoid scare tactics. Authoritative parenting (warm + firm + clear expectations) is associated with lowest adolescent substance use rates.

70. Does cannabis affect school performance?

Yes. Regular adolescent use is associated with lower GPA, increased absenteeism, impaired attention and memory, and lower graduation rates. Driven by hippocampal memory disruption, prefrontal executive dysfunction, and motivational effects. Performance typically improves with cessation.

71. Is teen cannabis use increasing?

Overall rates have remained relatively stable (MTF data). However, consumption has shifted to vaping and edibles, potency has skyrocketed, and risk perception has plummeted (21% of seniors view regular use as high-risk, down from 79% in 1991). Stable prevalence may mask worsening exposure intensity.

72. What is the legal age for cannabis?

21 in states with legal recreational cannabis, same as alcohol. Medical cannabis age varies by state; some allow minors with parental consent and physician recommendation. Despite age-21 laws, adolescent access remains substantial through social sources, older peers, and the illicit market.

73. How does puberty affect cannabis vulnerability?

Cannabis during puberty may disrupt hormonal and neurological development. The ECS interacts with the hypothalamic-pituitary-gonadal axis controlling puberty. THC may affect hormone production, pubertal milestones, and the reward system during critical reorganization. The brain is particularly sensitive during this period.

74. Can cannabis stunt a teenager's growth?

Limited evidence for direct physical growth effects. Cannabis may affect growth indirectly through appetite regulation, sleep quality (REM suppression reduces growth hormone), and hormonal disruption. The more significant concern is impaired brain development, cognitive maturation, and academic/social development.

75. How do teens get cannabis in legal states?

Primarily through social sources: friends, older siblings, parents' supplies, parties. Some access the illicit market. Legalization has increased downstream availability despite age restrictions. Dr. Sultan's Pediatrics 2026 study documented concerning access trends in legalized environments. See Legalization Impact.

76. What should parents do about a teen's vape pen?

Stay calm, wait 24-48 hours. Ask: is it theirs? How often? THC or nicotine? Assess motivation (curiosity, peers, self-medication). Set clear expectations. Schedule professional evaluation. If regular THC use, consult a psychiatrist experienced in adolescent substance use.

77. Does peer pressure drive teen cannabis use?

Peer influence is the single strongest environmental predictor of adolescent cannabis use. Often subtle social normalization rather than overt pressure. When use is common in a teen's circle, abstaining feels like a social risk. The desire to belong is among the most powerful forces in adolescent psychology.

78. What protects teens from cannabis use?

Protective factors: strong family connection, school engagement, extracurricular activities (especially athletics), treated mental health conditions, parental monitoring (warm, not surveillance), accurate risk perception, delayed first use, and having a trusted adult to confide in. Family dinners 5+ times/week reduce risk by 33% (CASAColumbia).

79. When should parents seek professional help?

Seek help if your teen: uses daily or near-daily, cannot stop despite trying, shows academic decline, has psychotic symptoms (paranoia, hallucinations), is using to cope with anxiety/depression/ADHD, combines cannabis with other substances, or expresses suicidal thoughts. Do not wait for the situation to resolve on its own.

80. What treatment works best for teens?

Family-based therapies (MDFT, FFT) are among the most effective for adolescent substance use. MET is particularly effective with ambivalent teens. CBT builds coping skills. Treating underlying conditions (ADHD, anxiety, depression) is essential. Only 36.8% of adolescents complete CUD treatment -- engagement is the critical challenge.

81. What are edibles?

Food or beverage products infused with THC: gummies, chocolates, cookies, beverages. Delayed onset (30-120 min) due to digestion. Liver converts THC to 11-OH-THC (2-3x more potent). Effects last 6-10 hours. Delayed onset frequently leads to overconsumption. See Cannabis Vaping & Edibles.

82. Why are edibles more intense than smoking?

Hepatic first-pass metabolism converts THC to 11-hydroxy-THC, which crosses the blood-brain barrier more efficiently and is 2-3x more psychoactive. This metabolite is not produced significantly when cannabis is smoked. Combined with overconsumption from delayed onset and 6-10 hour duration, edibles produce qualitatively different experiences.

83. Is vaping cannabis safer than smoking?

Vaping avoids combustion (less tar, CO). However, it introduces EVALI risk (2,807 hospitalizations, 68 deaths), exposure to unknown additives and heavy metals, and delivers much higher THC concentrations (60-90%). "Safer than smoking" does not mean "safe." Long-term respiratory effects are unknown.

84. How potent is modern cannabis vs. the 1990s?

Average flower THC: ~4% (1995) to >16% (2022) -- 4x increase. Vapes: 60-90% THC. Concentrates: 60-95% THC -- 15-25x increase over 1990s. This potency revolution has outpaced research and regulation. Comparing modern products to 1990s "weed" is pharmacologically misleading.

85. What are cannabis concentrates?

Products with concentrated THC (60-95%): shatter, wax, budder, live resin, rosin. Consumed by vaporizing on heated surfaces ("dabbing"). Extreme potency accelerates tolerance, increases dependence risk, and carries higher psychosis risk than flower.

86. What is the recommended edible dose?

Standard serving: 5-10 mg THC. Experts recommend 2.5 mg or less for inexperienced users. Wait at least 2 hours before re-dosing. Individual tolerance varies enormously. Dr. Sultan's AJPM 2025 study found labels may not accurately reflect actual THC content, adding dosing uncertainty.

87. What is delta-8 THC?

A minor cannabinoid, psychoactive but less potent than delta-9 THC. Most commercial delta-8 is synthetically converted from hemp CBD, creating regulatory ambiguity under the 2018 Farm Bill. Products are poorly regulated, inconsistently tested, and may contain harmful conversion byproducts. Several states have banned them.

88. What is full-spectrum vs. isolate CBD?

Full-spectrum: all cannabinoids (including trace THC under 0.3%), terpenes, plant compounds. Broad-spectrum: multiple cannabinoids, THC removed. Isolate: pure CBD only. Full-spectrum may benefit from "entourage effect" but carries small drug test risk. Isolate eliminates this risk.

89. Can you identify cannabis edibles by appearance?

Generally no. Modern edibles look, taste, and smell like regular candy, cookies, and beverages. This is a safety concern for children. Once removed from packaging, most are indistinguishable from regular food. Proper storage in labeled, child-proof containers is critical.

90. What is THCA?

THCA is the non-psychoactive precursor to THC in raw cannabis. Heat (decarboxylation) converts THCA to active THC. Raw cannabis does not produce a high. Some claim THCA health benefits, but clinical evidence is limited. THCA products have entered a regulatory gray area.

91. How do tinctures work?

Liquid cannabis extracts in alcohol or oil (MCT). Sublingual: faster absorption (15-45 min). Swallowed: slower, edible-like effects (30-120 min). Allow more precise dosing via drops/mL. No odor or residue. Effects last 4-8 hours depending on administration.

92. What is live rosin?

A solventless concentrate made by applying heat and pressure to fresh-frozen cannabis. Contains 60-80% THC. Considered "cleaner" because no chemical solvents are used. Despite being solventless, live rosin carries the same mental health risks as other high-potency concentrates due to extreme THC concentration.

93. Are cannabis beverages safer than edibles?

Cannabis beverages use nano-emulsion technology for faster onset (15-30 minutes vs. 30-120 for traditional edibles). Faster onset allows better dose titration and reduces overconsumption risk. However, they still produce oral THC effects and carry the same risk of impairment. The lower barrier to consumption (drinking vs. eating unusual candy) may increase casual use.

94. What is the safest way to use cannabis?

From a harm reduction perspective: lower-potency flower (under 15% THC), infrequent use (weekly or less), never during adolescence, avoid combining with alcohol, do not drive after use, do not use during pregnancy/breastfeeding. The lowest risk is non-use. For those who choose to use, lower potency and lower frequency reduce risk substantially.

95. Are cannabis product labels accurate?

Not always. Dr. Sultan's AJPM 2025 study found significant discrepancies between labeled and actual THC content in NYC dispensary products. Some contained more THC (overconsumption risk), others less (quality control failure). Contaminants were also identified. Labeling accuracy remains a significant industry-wide problem.

96. Does medical cannabis have legitimate uses?

Yes, for specific conditions. FDA-approved: Epidiolex (CBD) for seizure syndromes; dronabinol/nabilone (synthetic THC) for chemo nausea and AIDS wasting. Moderate evidence: neuropathic pain, MS spasticity. Limited evidence for most other commonly cited conditions. The gap between evidence and prescribing is significant.

97. How strong is the evidence for medical marijuana?

Varies dramatically by condition. Strong: specific seizure disorders, chemo nausea. Moderate: neuropathic pain, MS spasticity. Limited/insufficient: anxiety, depression, PTSD, insomnia, general chronic pain. The 2017 National Academies report found conclusive evidence for only a few indications out of dozens cited.

98. Can cannabis interact with medications?

Yes. THC and CBD inhibit CYP3A4 and CYP2C9 liver enzymes, affecting metabolism of warfarin, SSRIs, benzodiazepines, statins, and immunosuppressants. CBD has significant interactions with clobazam. Always discuss cannabis use with prescribers. Drug interactions can alter medication blood levels unpredictably.

99. Should I tell my psychiatrist I use cannabis?

Yes. Always. Cannabis interacts with medications, affects treated conditions, and is essential for accurate diagnosis. Psychiatrists are bound by confidentiality, not law enforcement. Withholding information leads to misdiagnosis, inappropriate medications, and ineffective treatment. Honest disclosure enables better care.

100. Is CBD approved by the FDA?

Only Epidiolex (pharmaceutical CBD) for seizures (Dravet, Lennox-Gastaut, tuberous sclerosis complex). Over-the-counter CBD products are NOT FDA-approved and are minimally regulated. FDA has issued warning letters to companies making unsupported health claims. Do not confuse FDA-approved Epidiolex with unregulated CBD supplements.

101. Can cannabis treat chronic pain?

Moderate evidence for chronic neuropathic pain specifically. Weaker evidence for other pain types. The 2017 National Academies found substantial evidence for pain relief, though effect sizes were modest. Not recommended as first-line treatment. Risk-benefit must be weighed against mental health risks of chronic use.

102. Does cannabis cure cancer?

No. Some preclinical studies show cannabinoids inhibit tumor growth in vitro, but this has not been replicated in human trials. Patients who forgo proven treatments for cannabis are risking their lives. Cannabis has a legitimate supportive role for chemo nausea and cancer pain, but it is not a cancer treatment.

103. Can cannabis help with insomnia?

THC may reduce sleep onset time short-term but disrupts REM sleep and overall quality with chronic use. Tolerance develops quickly. Rebound insomnia upon cessation often exceeds the original problem. CBT for insomnia (CBT-I) is more effective and safer for long-term management.

104. Is medical cannabis regulated like other medications?

No. It has not undergone FDA approval (clinical trials, safety review, manufacturing standards). Programs vary by state. Product potency/purity varies between dispensaries. Patients have fewer safety assurances than with FDA-approved medications. This regulatory gap is a fundamental challenge for evidence-based prescribing.

105. Can cannabis help with epilepsy?

CBD has demonstrated efficacy: Epidiolex reduces seizure frequency by 40-50% for Dravet, Lennox-Gastaut, and tuberous sclerosis. THC-containing products have not shown seizure benefit and may lower seizure threshold. Do not self-medicate with unregulated products -- pharmaceutical CBD under medical supervision is the evidence-based approach.

106. Does cannabis help with nausea?

Yes for chemo-induced nausea: dronabinol and nabilone are FDA-approved for this indication, typically after conventional anti-emetics fail. Paradoxically, chronic heavy use causes CHS (severe cyclic vomiting). Cannabis should not be used as a general anti-nausea remedy without medical supervision.

107. What do psychiatrists think about medical cannabis?

Professional organizations (APA) take a cautious stance: acknowledge potential uses but emphasize insufficient evidence for psychiatric indications, mental health risks (especially psychosis), and concerns about self-medication replacing evidence-based treatments. Most support further research but are skeptical of broad therapeutic claims.

108. Can you build tolerance to medical cannabis?

Yes. Tolerance develops to both therapeutic and psychoactive effects with regular use, requiring escalating doses. This increases cost and risk. Tolerance develops fastest with daily use and high-potency products. Some programs recommend "tolerance breaks," though this approach lacks rigorous study in medical contexts.

109. Is CBD oil safe?

Pharmaceutical CBD (Epidiolex) is generally well-tolerated; common side effects include diarrhea, drowsiness, and liver enzyme elevation. OTC CBD products are minimally regulated -- studies find many do not contain the labeled CBD amount and some contain undisclosed THC. Choose products with third-party testing certificates.

110. Can cannabis be used alongside psychiatric medication?

Cannabis can interact with psychiatric medications via cytochrome P450. THC enhances sedation from benzodiazepines. CBD inhibits CYP3A4/CYP2C9, potentially increasing levels of SSRIs, antipsychotics, and mood stabilizers. Cannabis can counteract therapeutic effects -- e.g., worsening psychosis despite antipsychotic treatment. Always discuss with your prescriber.

111. Is cannabis legal in all states?

No. As of 2026, 24 states + D.C. have legalized recreational cannabis (21+). 14 additional states have medical programs. Cannabis remains Schedule I federally. Even in legal states, regulations vary for purchase limits, cultivation, consumption, and employer testing. Federal employees remain subject to prohibition. See Legalization Impact.

112. Has legalization reduced crime?

Cannabis arrests have dropped significantly, disproportionately benefiting Black and Latino communities. The illicit market persists in all legal states. Research on non-cannabis crime is mixed -- no consistent evidence of increases or decreases in violent or property crime attributable to legalization.

113. Can you get fired for using cannabis in a legal state?

In most states, yes. Most allow employer drug-free workplace policies. Some states (CA, NY, NJ) have enacted off-duty protections with exceptions for safety-sensitive positions and federal contractors. Know your state's specific employment protections before assuming legal use means workplace protection.

114. Can you drive after using cannabis?

No. Illegal in all states and unsafe. Cannabis impairs reaction time, coordination, attention, and judgment. Approximately doubles accident risk (Asbridge et al., 2012). No consensus on a THC impairment threshold, unlike the 0.08 BAC for alcohol. Effects persist 3-6 hours (inhalation) or longer (edibles). Never drive after using.

115. What is the federal status of cannabis?

Schedule I ("high abuse potential, no accepted medical use"). Widely criticized as inconsistent with evidence. HHS recommended Schedule III reclassification in 2023; DEA is reviewing. Rescheduling would not legalize recreational cannabis but would reduce research barriers, resolve banking issues, and enable tax deductions for cannabis businesses.

116. Has legalization increased traffic accidents?

Research suggests modest increases: 5-6% more traffic fatalities in Colorado and Washington post-legalization. THC detection in fatal crash drivers is increasing nationally. Disentangling cannabis effects from concurrent trends is methodologically challenging. Cannabis-impaired driving remains underenforced compared to alcohol.

117. What is the "gateway drug" theory?

No evidence for a simple pharmacological gateway mechanism. However, early cannabis use is statistically associated with subsequent other substance use through shared risk factors (genetics, environment, mental health), behavioral normalization, and illicit market exposure. Most cannabis users never use other illicit drugs.

118. How does legalization affect the illicit market?

Legalization has reduced but not eliminated the illicit market. It persists due to lower prices (no taxes), no age restrictions, and established networks. In California, the illicit market is estimated at 2-3x the legal market. Persistent illicit products have no testing, labeling, or safety requirements.

119. Can dispensaries operate near schools?

Most states prohibit dispensaries within 500-1,000 feet of schools. Enforcement varies. Emerging research suggests associations between dispensary density and increased cannabis use in nearby populations. Buffer zone adequacy and enforcement are active policy debates in legalized states.

120. How is cannabis taxed?

Varies by state: combinations of excise taxes, sales taxes, and cultivation taxes. Total rates range from ~15% to 40%+. Most states use flat rates regardless of potency -- unlike alcohol's potency-based taxation. This policy gap fails to account for differential risks of high-potency products.

121. What is federal cannabis rescheduling?

Moving cannabis from Schedule I to a lower schedule. HHS recommended Schedule III in 2023; DEA reviewing. Schedule III would: acknowledge medical use, reduce research barriers, enable tax deductions (blocked by 280E), and reduce federal-state conflict. Would NOT legalize recreational cannabis federally.

122. Can you travel with cannabis between legal states?

No. Interstate transport is a federal crime regardless of state legality. Applies to driving, flying, and shipping. TSA defers to local law enforcement but federal law technically applies in airports. Even between two legal states, crossing state lines with cannabis is federally illegal.

123. What are social equity provisions?

Legalization provisions addressing disproportionate prohibition impact on communities of color: prioritized licensing, conviction expungement, tax revenue reinvestment, and reduced entry barriers. Implementation has been inconsistent. Many programs have failed to deliver meaningful outcomes for affected communities.

124. Does legalization normalize drug use for youth?

Legalization contributes to decreased risk perception among youth (21% of seniors view regular use as high-risk, down from 79% in 1991). Visible dispensaries, advertising, and adult normalization accelerate this trend. Whether decreased risk perception translates to increased use is debated -- prevalence is stable but products are far more potent.

125. What would federal legalization mean?

Would enable FDA product regulation, resolve banking challenges, remove interstate transport prohibitions, reduce research barriers, allow VA cannabis access, and resolve federal-state conflict. The specific regulatory framework would determine public health outcomes. Without potency limits, marketing restrictions, and youth protections, federal legalization could worsen current problems.

Have Questions About Cannabis and Your Mental Health?

Dr. Ryan Sultan provides expert evaluation and treatment for cannabis-related concerns. As an NIH NIDA-funded researcher at Columbia University and Director of Integrative Psych NYC, he combines deep research expertise with individualized clinical care.

Telehealth appointments available | Board-Certified Psychiatrist | Columbia University Faculty

© 2026 Ryan S. Sultan, MD | Assistant Professor of Clinical Psychiatry, Columbia University Irving Medical Center
Home | Cannabis & Mental Health | Research | Consultation

The information on this page is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition.